Insurance Guide · Last verified June 12, 2026

Aetna Zepbound Prior Authorization: 2026 Criteria, Checklist, and Denial Fixes

By The RX Index Editorial Team · Last verified: June 12, 2026

The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. Some links on this page are affiliate links — we may earn a commission if you use them. That never changes what we report. We cite our sources throughout, with the full list at the end. This guide is general information, not medical or coverage advice. Your clinician and your Aetna plan documents control your actual care and coverage.

Here’s the straight answer on Aetna Zepbound prior authorization: if your plan covers Zepbound, Aetna’s published criteria focus on two things for weight loss — a BMI of 30 or higher (or 27+ with a weight-related condition like high blood pressure or type 2 diabetes), plus six documented months in a real weight-management program before the medication. For sleep apnea, it’s a sleep-study score and a BMI. But here’s what most guides skip: many Aetna plans dropped Zepbound from their formulary on July 1, 2025, so the PA criteria are moot if your plan excluded the drug entirely. Your first move is figuring out which of six different situations you’re actually in — the table below takes 90 seconds.

Which Aetna situation are you in? Start here

Does Aetna cover Zepbound in 2026 — or is it excluded on your plan?

Aetna coverage for Zepbound depends on your specific plan and formulary. Many Aetna commercial plans removed Zepbound for weight loss on July 1, 2025, when CVS Caremark — the pharmacy benefit manager that runs the drug side of most Aetna plans — made Wegovy the preferred GLP-1 on its standard formularies. Other Aetna plans still cover Zepbound with prior authorization, and CVS Caremark has announced Zepbound returns to certain commercial formularies on October 1, 2026 for plan sponsors who elect to provide coverage.

Quick definitions so the rest of this page makes sense. A formulary is your plan’s list of covered drugs. A pharmacy benefit manager (PBM) is the company that runs the prescription side of your insurance — for most Aetna plans, that’s CVS Caremark, an affiliated company (both are part of CVS Health). Prior authorization (PA) means your doctor has to prove you meet the plan’s rules before it pays.

When you check your plan, you’ll see one of three labels. They are not the same problem:

1. “Prior authorization required.” Good news, relatively. Zepbound is on your formulary. Your doctor documents the criteria, Aetna reviews, and coverage can follow.
2. “Non-formulary” or “preferred alternatives required.” Zepbound was pulled from your drug list. Aetna’s own 2026 Standard Control Plan exclusion list shows Zepbound removed, with liraglutide, orlistat, Qsymia, and Wegovy listed as covered options. The fix here is a formulary exception — a request to cover a non-listed drug for medical reasons — not a standard PA. Big difference. The recognized trigger: you already tried Wegovy and it didn’t work well enough, or you have a documented medical reason Wegovy isn’t appropriate.
3. “Weight-loss drugs not covered.” The category exclusion we warned you about above. Check whether the sleep apnea benefit still exists separately — it often does — then see the cash options.

How to check your exact plan in 5 minutes

1. Log in at Aetna.com or the Aetna app, open “Find a Medication,” and search Zepbound.
2. Read the label next to it: covered, PA, step therapy, quantity limit, or excluded.
3. No login handy? Call the number on your member ID card and read this script:

“I’m checking my pharmacy benefit. Is Zepbound — Z-E-P-B-O-U-N-D — covered on my plan for weight management? Is it covered for obstructive sleep apnea? Does it require prior authorization or step therapy? If it’s excluded, does my plan allow a formulary exception, and is my employer adopting the October 1, 2026 formulary change that adds Zepbound back?”

Is Zepbound coming back to Aetna and CVS Caremark plans? Yes — partly — October 1, 2026

On May 28, 2026, CVS Caremark announced it will add Zepbound back to commercial formularies as an additional preferred option starting October 1, 2026, for plan sponsors who elect to provide coverage — reversing the July 2025 removal. Employers decide whether to adopt the change, so it will reach some Aetna members and not others. Caremark also lifted its new-to-market block on Foundayo (orforglipron), Lilly’s daily GLP-1 pill, on June 1, 2026.

If you’ve been told “Zepbound isn’t covered, period” — that answer may have an expiration date. Here’s the full timeline:

The plan-adoption questions to ask HR or Aetna

What are the Aetna Zepbound prior authorization criteria? The full checklist

For weight management, Aetna’s published non-Medicare criteria require a BMI of 30 or higher, OR a BMI of 27 or higher with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia — plus documentation of a comprehensive weight-management program (reduced-calorie diet, more physical activity, behavior changes, and ongoing follow-up) for at least six months before drug therapy. Aetna’s published policy lists an initial approval of 8 months for weight management and 6 months for sleep apnea, with a 12-month continuation when criteria are met.

BMI — body mass index — is a height-to-weight ratio. A 5’6” adult at about 186 lbs is right at BMI 30. Your doctor’s office calculates it from a recorded weigh-in.

Most denials aren’t “you don’t qualify.” They’re “you didn’t prove you qualify.” Aetna’s reviewer can only approve what’s in the packet. Print this and bring it to your appointment:

The Aetna Zepbound PA Evidence Matrix

Sources: Aetna’s published Zepbound clinical policy bulletins and precertification form, verified June 2026 (links at the bottom).

Can Aetna approve Zepbound for sleep apnea? The second pathway

Yes. Zepbound is the only FDA-approved medication for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity — approved in December 2024 — and Aetna’s published criteria for this pathway require an apnea-hypopnea index (AHI) of 15 or higher on a sleep study (in-lab polysomnography or an adequate home sleep apnea test), plus a BMI of 30 or higher. Some Aetna plans that removed Zepbound for weight loss still cover it under the sleep apnea benefit.

Plain English: OSA means your airway gets blocked while you sleep, so you stop breathing in short bursts. AHI is the score from a sleep study — how many times per hour your breathing pauses or goes shallow. Fifteen or more per hour is “moderate.” The study can happen in a sleep lab (polysomnography, or PSG) or at home with a prescribed device (a home sleep apnea test, or HSAT).

Your OSA packet needs:

• The OSA diagnosis in your chart
• The sleep-study report showing AHI ≥ 15, with the test date and type (PSG or home test)
• A recorded BMI ≥ 30
• A clinician note stating Zepbound is being prescribed for OSA

Renewals on this path look at symptoms: Aetna’s continuation language requires the established OSA diagnosis plus a documented positive response — decreased OSA symptoms.

What should your doctor put in the Aetna Zepbound PA packet? Copy this

A strong Aetna Zepbound PA packet makes the reviewer’s job easy: diagnosis with ICD code, current and baseline BMI and weight, the six-month program documentation with dates, any weight-related conditions with labs, sleep-study results if filing under OSA, prior medication history if relevant, and a prescription quantity that matches plan limits. Aetna’s own precertification form asks for diagnosis, diagnostic testing, lab values, and step-therapy details — incomplete fields are the top cause of fast denials.

Your doctor files the PA — you can’t submit it yourself. But you can make sure nothing’s missing. Send this through your patient portal:

Hi — I’m trying to avoid a “missing information” denial on my Aetna prior authorization for Zepbound. When your office submits it, could you please include: my diagnosis and ICD code; my baseline and current weight, height, and BMI; documentation of my 6-month weight-management program with visit dates; my weight-related conditions and supporting labs (blood pressure, A1c, lipids) if my BMI is under 30; my sleep-study report and AHI score if we’re filing under sleep apnea; any prior weight medications I’ve tried; and a quantity that matches Aetna’s limit. Thank you — happy to send anything you need from my side.

We wrote that so you can paste it straight into your portal. Copy it.

Where does your prescriber submit the Aetna Zepbound PA?

Aetna’s prescription-drug precertification form lists Availity for online submission, separate fax lines for non-specialty and specialty drug requests, and a pharmacy precertification phone line for the fastest service. Your prescriber’s office picks the channel that matches your plan and the drug category. If your office isn’t sure where to send it, the phone line on Aetna’s precertification form gets a human on the line faster than fax.

Honest reality check: paperwork is the bottleneck. If your doctor’s office is responsive, this route is free and works. If they’re slammed — or you’re using a telehealth service that doesn’t touch insurance — there’s a managed option. Ro’s Body program includes an insurance concierge that verifies your Aetna coverage and handles the prior authorization paperwork for eligible patients, and Ro carries FDA-approved Zepbound pens. Set your expectations right: the insurance side takes a couple of weeks, not a day. Membership is $39 for the first month, then as low as $74/month with the annual plan paid upfront (or $149/month month-to-month). The medication cost is separate, billed through your insurance or the cash price. Ro cannot guarantee Aetna says yes — nobody can — but you stop being the project manager.

How long does Aetna prior authorization take for Zepbound?

Aetna doesn’t publish one universal Zepbound PA timeline. A complete packet moves faster than one missing information, and published patient-experience estimates generally land between a few days and about two weeks. The safest process is to confirm the PA was actually submitted, ask whether Aetna needs anything else, and request expedited review only when your prescriber attests that waiting would seriously harm your health.

One thing worth knowing: this is a national problem, not a you problem. KFF polling finds about half of GLP-1 users say the drugs were difficult to afford, and a quarter said “very difficult.” The system is the obstacle. Treat it like a process, not a verdict.

Why was your Aetna Zepbound prior authorization denied? The decoder

An Aetna Zepbound denial isn’t one problem — it’s seven different problems wearing the same letter. The wording tells you whether to resubmit with better documents, request a formulary exception, fix a prescription quantity, or stop fighting and pivot. Match your letter to the row below before doing anything else.

A real case shows what’s at stake. In reporting on the CVS Caremark class action, one patient lost more than 60 pounds in about five months on Zepbound, then regained weight after losing access through the formulary change. His doctors sent dozens of letters through repeated appeal denials, and his story became part of the federal lawsuit. If Wegovy genuinely didn’t work for you, that history is your strongest evidence. Get it in writing, in your chart, with dates.

How do you appeal an Aetna Zepbound denial — and when should you skip the appeal?

Aetna members generally have 180 days from a denial notice to file an internal appeal (some plans allow longer), with decision timelines that vary by plan type and urgency. Appeals often succeed when the denial is clinical or administrative — an AMA/KFF analysis of Medicare Advantage data found over 80% of prior-authorization appeals were overturned — but appeals rarely beat a plan-wide weight-loss benefit exclusion. Match the tool to the wall.

That 80% figure is Medicare Advantage data, not a promise about your Aetna commercial plan — but it tells you something real: when a denial is about clinical evidence or paperwork, the appeal is very winnable.

Appeals are won by organized people with deadlines on a calendar. Don’t let the 180-day window close while you decide. If a step-therapy block is your real problem, our Aetna GLP-1 step therapy guide covers exactly what your doctor needs to document.

What does Zepbound cost if Aetna approves it — or refuses?

If Aetna approves Zepbound, you pay your plan’s copay or deductible amount — and commercially insured patients with coverage can use Lilly’s Zepbound Savings Card to pay as little as $25/month, subject to eligibility and monthly and annual limits (current terms run through December 31, 2026). If Aetna says no, FDA-approved cash routes now start at $299/month through LillyDirect and TrumpRx.

Paying cash while you appeal — or while you wait for October 1? That hybrid play is legitimate and common: cash now, switch to insurance when approval lands. Ro fills brand-name Zepbound pens with the medication priced to match LillyDirect, and the prescription, dose adjustments, and follow-up care are built into the membership — so you’re not buying vials and figuring out syringes alone.

Should you use your own doctor, Ro, Sesame, or LillyDirect? Pick your lane

The right route depends on what’s blocking you: use your own doctor if your chart already holds the BMI, comorbidity, and 6-month program records; use Ro if you want one service to verify Aetna coverage, file the PA, and fall back to matched cash pricing; use Sesame Care if you want to choose your own clinician and pay per visit; use LillyDirect if you only need the lowest cash price and already have a prescriber. No route can guarantee Aetna approval.

Aetna Medicare and Medicaid: different rules, and a $50 door opening July 1

Medicare Part D plans — including Aetna’s — can’t cover weight-loss drugs under standard rules, but two doors exist in 2026: the sleep apnea indication (coverable under Part D with prior authorization), and the new Medicare GLP-1 Bridge, a CMS pilot running July 1, 2026 through December 31, 2027 that provides the Zepbound KwikPen for a flat $50/month to eligible Part D enrollees. Vials and single-dose pens are NOT included, prior authorizations won’t be processed before July 1, and the $50 sits outside the normal Part D benefit — it doesn’t count toward your deductible or the $2,100 out-of-pocket cap.

Who qualifies for the Bridge. CMS says you must be at least 18 and meet one of:

• BMI of 35 or higher, or
• BMI of 30 or higher plus certain heart or kidney conditions — a type of heart failure (HFpEF), high blood pressure that two medications haven’t controlled, or moderate-to-advanced kidney disease (stage 3a or worse), or
• BMI of 27 or higher plus prediabetes, a past heart attack or stroke, or peripheral artery disease (narrowed arteries in the limbs).

The details Medicare readers actually need:

• Which drugs. CMS includes all formulations of Foundayo, all formulations of Wegovy, and only the Zepbound KwikPen. The Zepbound single-dose vial and single-dose pen are not included — ask your prescriber to write the KwikPen.
• The Bridge is for weight management. If you take Zepbound for type 2 diabetes or sleep apnea, those are separate Part D paths, not the Bridge.
• Your provider files the Bridge PA — and CMS won’t accept or process requests before July 1, 2026. Calling earlier changes nothing.
• A BMI grace note: if you started GLP-1 therapy earlier at a qualifying BMI and have since lost weight below the line, your prescriber can attest you met the bar at the start. Don’t let progress disqualify you on paper.
• The math: manufacturers supply the drugs at a $245 net price; you pay $50; the program “bridges” to a longer-term model that, notably, has already been delayed.

For the complete walkthrough — enrollment, pharmacy logistics, what happens after 2027 — see our dedicated guide: The Medicare GLP-1 Bridge, explained →

What can block a Zepbound prescription even if Aetna would pay?

Insurance approval and medical eligibility are separate gates. Zepbound’s FDA labeling lists contraindications — a personal or family history of medullary thyroid carcinoma (a rare thyroid cancer), Multiple Endocrine Neoplasia syndrome type 2, or a prior serious allergic reaction to tirzepatide — plus warnings including pancreatitis risk and avoiding use in pregnancy. Common side effects include nausea, diarrhea, vomiting, constipation, and injection-site reactions, especially while the dose is increasing.

Your clinician also screens for other label warnings — severe stomach or intestinal problems, kidney injury from dehydration, gallbladder problems, low blood sugar when Zepbound is used with insulin or certain diabetes pills, and serious allergic reactions. A coverage win is not a green light. Aetna reviews whether the plan pays; your clinician decides whether Zepbound is medically right for you. If your prescriber hesitates, ask why — the answer might be one of the items above, and that conversation matters more than any form on this page.

You got approved. Now protect the renewal.

Aetna’s initial Zepbound approvals are time-limited — 8 months for weight management, 6 months for sleep apnea — and renewal (a 12-month continuation when criteria are met) requires documentation: a stable maintenance dose plus at least 5% weight loss from baseline on the weight-management path, and documented symptom improvement on the OSA path. The renewal denial is the most preventable denial in this entire process — and the prevention takes five minutes a month.

Start a simple log today — a notes app is fine:

• Baseline weight and date (the number everything is measured against)
• Monthly weigh-ins, same scale, same time of day — and get a few into your chart at visits, because Aetna trusts chart weights, not screenshots
• Dose changes with dates
• Refill dates (your fill history shows you’re actually taking it)
• OSA path: symptom notes — energy, snoring, daytime sleepiness
• A reminder set for 45 days before your approval expires, so your doctor renews early instead of you rationing pens during a gap

Six months from now, your renewal will take ten minutes instead of three panicked weeks. You’ll be glad past-you was this boring.

Frequently asked questions

How we built and verified this guide

We are The RX Index — a pricing intelligence and comparison resource for GLP-1 telehealth providers. For this guide, we read Aetna’s published Zepbound clinical policy bulletins (the weight-management and sleep-apnea versions, including approval durations and quantity limits), Aetna’s 2026 Standard Control Plan exclusion list, Aetna’s precertification form and member appeal pages, CVS Caremark’s formulary announcements including the May 28, 2026 reinstatement, CMS’s Medicare GLP-1 Bridge documentation, FDA approval records, Lilly’s pricing and savings terms, federal court filings from the CVS Caremark class action, state plan documents, and the providers’ own published pricing. Every price and date carries the verification stamp at the top of the page, and we re-check the volatile items monthly. We earn affiliate commissions from some providers we link to, including Ro and Sesame Care — and our standing rule is that accuracy and your trust come first, ahead of any commission.